Actinomycin D
Summary
Actinomycin D (dactinomycin) is a chemotherapeutic antibiotic that intercalates into DNA, inhibiting RNA polymerase and blocking transcription. It is primarily used to treat pediatric cancers such as Wilms tumor, rhabdomyosarcoma, and Ewing sarcoma, as well as gestational trophoblastic disease. Key toxicity includes myelosuppression and radiosensitization effects.
Detail
Actinomycin D is a natural antibiotic derived from Streptomyces species that functions as an antineoplastic agent through DNA intercalation. It binds to the minor groove of double-stranded DNA at GC-rich sequences, preventing the DNA template from being used effectively by RNA polymerase, thereby inhibiting transcription (mRNA synthesis). At higher concentrations, it can also inhibit DNA replication by interfering with topoisomerase II.
Mechanism: The planar phenoxazone ring intercalates between adjacent GC base pairs, while the peptide side chains interact with the minor groove, creating a stable drug-DNA complex that blocks RNA polymerase progression.
Clinical uses: Actinomycin D is part of combination chemotherapy regimens for several pediatric solid tumors, most notably Wilms tumor (nephroblastoma), rhabdomyosarcoma, and Ewing sarcoma. It is also used in the treatment of gestational trophoblastic neoplasia (choriocarcinoma) and some testicular cancers.
Adverse effects: Major toxicities include bone marrow suppression (leukopenia, thrombocytopenia), nausea/vomiting, mucositis, and alopecia. It is a potent radiosensitizer, so concurrent radiation therapy increases toxicity risk, including radiation recall dermatitis. Extravasation can cause severe tissue necrosis.
High-yield board association: Actinomycin D is classically tested as part of the VAC regimen (Vincristine, Actinomycin D, Cyclophosphamide) used for Wilms tumor and rhabdomyosarcoma. Students should remember it as a transcription inhibitor via DNA intercalation, distinguishing it from other intercalating agents like doxorubicin (which also generates free radicals and causes cardiotoxicity).
Sources
- First Aid for the USMLE Step 1
- Katzung's Basic and Clinical Pharmacology
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
- UpToDate: Dactinomycin drug monograph
Reviewed by Medusa editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.